Mounjaro remained the company's biggest growth driver, generating $9.94 billion in worldwide sales during the quarter, up 91% from a year earlier. The diabetes drug posted particularly strong international growth, with revenue outside the United States climbing 172%, while U.S. sales reached $4.8 billion. The results also included the first quarterly contribution from Foundayo, Lilly's oral GLP-1 obesity pill, which received U.S. regulatory approval in April. The drug generated $98 million in revenue during the quarter, slightly below analyst estimates of about $103 million, according to FactSet. Flush with cash from its obesity franchise, Lilly has continued an aggressive acquisition strategy this year.